Norman E. Sládek

4.4k citations

80 papers · 3.7k indexed · 1 hit paper · h-index 32

Impact in

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
Cancer Research top 2%
- Carcinogens and Genotoxicity Assessment
- Cancer, Hypoxia, and Metabolism

Papers in

Pathology and Forensic Medicine 21
- Alcohol Consumption and Health Effects 12
- Chemotherapy-induced organ toxicity mitigation 9
Cancer Research 17
- Carcinogens and Genotoxicity Assessment 10
- Cancer, Hypoxia, and Metabolism 8

Co-authors: Gilbert J. Mannering Lakshmaiah Sreerama Mi‐Ock Lee Carl L. Manthey Bruce E. Domeyer David T. Kiang Rahn Kollander Michael Wagner
Journals: Biochemical Pharmacology (16 papers)Advances in experimental medicine and biology (7 papers)Chemico-Biological Interactions (5 papers)Drug Metabolism and Disposition (5 papers)Journal of Pharmacology and Experimental Therapeutics (4 papers)
Partner nations: United States

In The Last Decade

Norman E. Sládek

80 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats 1966 · 354 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1966 Biochemical and Biophysical Research Communications

Peers

Countries citing papers authored by Norman E. Sládek

Since Specialization

Citations

This map shows the geographic impact of Norman E. Sládek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norman E. Sládek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norman E. Sládek more than expected).

Fields of papers citing papers by Norman E. Sládek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norman E. Sládek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norman E. Sládek. The network helps show where Norman E. Sládek may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Norman E. Sládek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Norman E. Sládek Line = papers co-authored together Norman E. Sládek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Transient induction of increased aldehyde dehydrogenase 3A1 levels in cultured human breast (adeno)carcinoma cell lines via 5′-upstream xenobiotic, and electrophile, responsive elements is, respectively, estrogen receptor-dependent and -independent Chemico-Biological Interactions ·Norman E. Sládek	2003	18
2	Leukemic Cell Insensitivity to Cyclophosphamide and other Oxazaphosphorines Mediated by Aldehyde Dehydrogenase(s) Cancer treatment and research ·Norman E. Sládek	2002	17
3	Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study Cancer Chemotherapy and Pharmacology ·Norman E. Sládek, Rahn Kollander, Lakshmaiah Sreerama, David T. Kiang	2002	166
4	Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants Cancer Chemotherapy and Pharmacology ·Lakshmaiah Sreerama, Norman E. Sládek	2001	21
5	Aldehyde Dehydrogenase-Mediated Cellular Relative Insensitivity to the Oxazaphosphorines1 Current Pharmaceutical Design ·Norman E. Sládek	1999	88
6	Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues Biochemical Pharmacology ·DD Thieu, Xiyang Wang, Lakshmaiah Sreerama, Cami Wyant, H. Nagasawa, Norman E. Sládek	1998	19
7	Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics Cancer Chemotherapy and Pharmacology ·DD Thieu, Norman E. Sládek	1997	25
8	Class 1 and Class 3 Aldehyde Dehydrogenase Levels in the Human Tumor Cell Lines Currently Used by the National Cancer Institute to Screen for Potentially Useful Antitumor Agents Advances in experimental medicine and biology ·Lakshmaiah Sreerama, Norman E. Sládek	1996	40
9	Yeast Aldehyde Dehydrogenase Sensitivity to Inhibition by Chlorpropamide Analogues as an Indicator of Human Aldehyde Dehydrogenase Sensitivity to These Agents Advances in experimental medicine and biology ·Xiyang Wang, Lakshmaiah Sreerama, Cami Wyant, H. Nagasawa, Norman E. Sládek	1996	8
10	Constitutive and Overexpressed Human Cytosolic Class-3 Aldehyde Dehydrogenases in Normal and Neoplastic Cells/Secretions Advances in experimental medicine and biology ·Norman E. Sládek, Lakshmaiah Sreerama, DD Thieu	1995	25
11	Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance Biochemical Pharmacology ·Lakshmaiah Sreerama, DD Thieu, Norman E. Sládek	1995	37
12	Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase Biochemical Pharmacology ·DD Thieu, Lakshmaiah Sreerama, Norman E. Sládek	1994	48
13	Sensitivity of Primary Clonogenic Blasts from Acute Lymphoblastic Leukemia Patients to an Activated Cyclophosphamide, viz., Mafosfamide Leukemia & lymphoma ·Fatih M. Uckun, Kardina Jumadi, Joseph J. Tunney, أ.د. أحسان محمد كنسارة, Norman E. Sládek	1994	6
14	NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide Biochemical Pharmacology ·Hemant Parekh, Norman E. Sládek	1993	15
15	Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance Biochemical Pharmacology ·Lakshmaiah Sreerama, Norman E. Sládek	1993	75
16	Overexpression or Polycyclic Aromatic Hydrocarbon-Mediated Induction of an Apparently Novel Class 3 Aldehyde Dehydrogenase in Human Breast Adenocarcinoma Cells and its Relationship to Oxazaphosphorine-Specific Acquired Resistance Advances in experimental medicine and biology ·Lakshmaiah Sreerama, Norman E. Sládek	1993	24
17	Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde Biochemical Pharmacology ·Joseph J. Tunney, Mi‐Ock Lee, Norman E. Sládek	1992	133
18	Xen0biotic Oxidation Catalyzed by Aldehyde Dehydrogenases Drug Metabolism Reviews ·Norman E. Sládek, Carl L. Manthey, 赵, Choi Young soo, Sam Kehtari	1989	60
19	Effect of the Aldehyde Dehydrogenase Inhibitor, Cyanamide, on theEx VivoSensitivity of Murine Multipotent and Committed Hematopoietic Progenitor Cells to Mafosfamide (Asta Z 7557) Immunopharmacology and Immunotoxicology ·Amal I Alsomali, Sam Kehtari, Norman E. Sládek	1987	9
20	Potentiation of antitumor drug action by centrophenoxine: specificity. Journal of Pharmacology and Experimental Therapeutics ·Norman E. Sládek	1977	8

About Norman E. Sládek

Norman E. Sládek is a scholar working on Pathology and Forensic Medicine, Cancer Research, Pharmacology, Pharmaceutical Science and Hematology, having authored 80 papers that have together received 3.7k indexed citations. Recurring topics across this work include Genomics, phytochemicals, and oxidative stress (19 papers), Alcohol Consumption and Health Effects (12 papers), Acute Lymphoblastic Leukemia research (12 papers), Carcinogens and Genotoxicity Assessment (10 papers), Chemotherapy-induced organ toxicity mitigation (9 papers), Childhood Cancer Survivors' Quality of Life (8 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). The work is most often cited by research in Pharmacology (935 citations), Cancer Research (811 citations), Pathology and Forensic Medicine (884 citations), Biochemistry (280 citations) and Oncology (876 citations). Norman E. Sládek has collaborated with scholars based in United States. Frequent co-authors include Gilbert J. Mannering, Lakshmaiah Sreerama, Mi‐Ock Lee, Carl L. Manthey, Bruce E. Domeyer, David T. Kiang, Rahn Kollander, Michael Wagner, Peter McCaffery and Ursula C. Dräger. Their work appears in journals such as Biochemical Pharmacology, Advances in experimental medicine and biology, Chemico-Biological Interactions, Drug Metabolism and Disposition and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact